Literature DB >> 18189032

Pulmonary and cutaneous sarcoidosis associated with interferon therapy for melanoma.

Fabien Pelletier1, Philippe Manzoni, Pascale Jacoulet, Philippe Humbert, François Aubin.   

Abstract

Interferon alfa is widely used as adjuvant therapy for melanoma. Numerous side effects have been attributed to interferon alfa. Interferon alfa-induced sarcoidosis is an uncommon event. We report the third case of pulmonary and cutaneous sarcoidosis in the course of interferon alfa treatment for melanoma. Most cases of sarcoidosis have been reported during treatment of chronic hepatitis C. The prognosis is good with discontinuation of treatment. Other than interferon therapy, sarcoidosis or granulomatosis reactions rarely have been reported in malignant melanoma. We discuss and review the literature on the physiopathology of sarcoidosis brought on by interferon therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18189032

Source DB:  PubMed          Journal:  Cutis        ISSN: 0011-4162


  4 in total

Review 1.  Development of sarcoidosis following completion of treatment for hepatitis C with pegylated interferon-{alpha}2a and ribavirin: a case report and literature review.

Authors:  Albéric-Rembrandt Gayet; Patrick Plaisance; Jean-François Bergmann; Stéphane Mouly
Journal:  Clin Med Res       Date:  2010-09-17

Review 2.  A review of adverse cutaneous drug reactions resulting from the use of interferon and ribavirin.

Authors:  Nisha Mistry; Jonathan Shapero; Richard I Crawford
Journal:  Can J Gastroenterol       Date:  2009-10       Impact factor: 3.522

Review 3.  Adaptive immune responses in primary cutaneous sarcoidosis.

Authors:  Matteo Bordignon; Paola Rottoli; Carlo Agostini; Mauro Alaibac
Journal:  Clin Dev Immunol       Date:  2011-03-30

Review 4.  Sarcoidosis in Melanoma Patients: Case Report and Literature Review.

Authors:  Bryce D Beutler; Philip R Cohen
Journal:  Cancers (Basel)       Date:  2015-06-15       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.